RxDoctor Payments DataLook up a doctor →

Denise Dickinson, MD

Dermatology · Louisville, KYNPI 1831267459

Payments from drug & device makers

$9,325in general payments, 2019–2025

Across 484 payments — averaging $19.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Johnson & Johnson$873
  • Sun Pharmaceutical Industries Inc.$861
  • Novartis$611
  • Biofrontera Inc.$544
  • Amgen$507
  • plus $4K from 28 others

What the payments were for

  • Speaking & faculty fees$3504%
  • Food & beverage$8,39290%
  • Education$5826%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,325 in reported general payments places this provider in the 75th percentile of 128 dermatology providers in Kentucky.

See all dermatology providers in Kentucky

Medicare billing

Part B allowed, 2024
$760,983
Medicare patients
377
Services billed
14,386

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast24$117,641
Dupixent PenDupilumab13$47,360
Dupixent SyringeDupilumab12$44,852
Doxycycline Hyclate95$8,116
Clobetasol Propionate147$7,019
Alclometasone Dipropionate58$3,163
Ketoconazole160$2,265
Fluorouracil39$2,254
Metronidazole29$2,097
Ammonium Lactate57$1,314
ValacyclovirValacyclovir Hcl21$1,276
Clindamycin Phosphate26$777
Levocetirizine Dihydrochloride90$530
Cephalexin27$359
Clindamycin Hcl19$162

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$507$117,64124 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 128 dermatology providers in Kentucky.

Other dermatology in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →